Naito, Y., Yoshikawa, T., Iinuma, S., Yagi, N., Matsu yama, K., Boku, Y., Fujii, T., Yoshida, N., Kondo, M. and Sasaki, E. (1998) Rebamipide protects against indomethacin-induced gastric mucosal injury in healthy volunteers in double-blind, placebo-controlled study. Digestive Diseases and Sciences, 43, 83S-89S.

has been cited by the following article:

• TITLE: Anti free radical & anti inflammatory effect of rebamipide in chronic gastritis

  AUTHORS: Marcellus Simadibrata, Ari Fahrial Syam, Aziz Rani, Septelia Inawati Wanandi, Achmad Fauzi, Murdani Abdullah

  KEYWORDS: Rebamipide; Chronic Gastritis; Histopathologic Severity; MDA; Carbonyl Compound

  JOURNAL NAME: Open Journal of Gastroenterology, Vol.3 No.1, February 28, 2013

  ABSTRACT: Background/Aim: Free radicals have a role in the development of chronic gastritis. The aim of this study to know the effect and efficacy of rebamipide on free radicals in chronic gastritis. Method: Forty five patients in the division gastroenterology Cipto Mangunkusumo Hospital Jakarta 2009-2010 with moderate and severe gastritis endoscopically were included in this study. Before and after rebamipide treatment the patient were performed endoscopical examination and were taken 5 biopsies for histopathological examination and free radicals (MDA & Carbonyl Compound) examination. All patients were given rebamipide 100 mg three times a day for 28 days. Data were analyzed with t test or wilcoxon signed rank test. Exclusion: GERD, Peptic ulcer, PPI treatment, NSAID consumption etc. The symptoms were recorded on day-0 and day-28. The severity symptoms were measured by VAS. Result: The mucosal damage on day-0 was 2.268 ± 0.45 vs day-28 was 1.707 ± 0.78 (P P = 0.710) and corpus neutrophil: day-0: 0.12 ± 0.40 vs day-28: 0.07 ± 0.26 (P = 0.421). The mean endoscopical mucosal severity score was decreased significantly on day- 28 compared to day-0 (1.707 ± 0.78 vs 2.268 ± 0.45; P P = 0.047). The mean of carbonyl compound on day-0 was 4.14 ± 3.01 and on day-28 was 5.12 ± 2.71 (P = 0.642). Conclusion: Rebamipide significantly reduced the extend of symptoms associated with chronic gastritis. The improvement in symptoms was associated with the decreased of endoscopic severity score and the mean gastric mucosal malondialdehyde (MDA) significantly but not the histopathologic appearance and carbonyl compound.